Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

Temozolomide 20Magnetic Resonance Spectroscopy 10Radiotherapy 9Blood Specimen Collection 8pembrolizumab 6Cyclophosphamide 6Bevacizumab 6AZD 6244 6Radiation 5Specimen Handling 4vorasidenib 3fludarabine 3cemiplimab 3aflutinib 3Surgical Procedures, Operative 3Saline Solution 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Pemetrexed 3Granulocyte-Macrophage Colony-Stimulating Factor 3tislelizumab 2osimertinib 2naxitamab 2gallium maltolate 2fludarabine phosphate 2dinutuximab 2Topotecan 2Standard of Care 2Spinal Puncture 2Receptors, Interleukin-8B 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × eliglustat × CNS × Clear all
NCT07090538 2025-07-29

GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.

Chinese PLA General Hospital

Phase EARLY_PHASE1 Not yet recruiting
10 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡